Biodesix to buy U.S. lab, lung nodule test from Oncimmune
The deal, which would become effective Nov. 1, is valued at up to $28 million over the next five years. Biodesix will acquire the UK company's US lab in Kansas.
The deal, which would become effective Nov. 1, is valued at up to $28 million over the next five years. Biodesix will acquire the UK company's US lab in Kansas.
Acquisition of Integrated Diagnostics gives Biodesix control of test to determine if nodules are benign or malignant.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.